Smithfield Trust Co. Sells 1,230 Shares of Bristol-Myers Squibb Co (BMY)

Smithfield Trust Co. lowered its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 5.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,381 shares of the biopharmaceutical company’s stock after selling 1,230 shares during the period. Smithfield Trust Co.’s holdings in Bristol-Myers Squibb were worth $1,390,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. CSat Investment Advisory L.P. acquired a new position in Bristol-Myers Squibb during the second quarter worth $113,000. Cypress Capital Management LLC WY grew its holdings in Bristol-Myers Squibb by 154.7% during the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 1,160 shares during the period. Landaas & Co. WI ADV acquired a new position in Bristol-Myers Squibb during the second quarter worth $131,000. Selective Wealth Management acquired a new position in Bristol-Myers Squibb during the third quarter worth $184,000. Finally, LFA Lugano Financial Advisors SA grew its holdings in Bristol-Myers Squibb by 85.8% during the third quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 1,481 shares during the period. 72.54% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:BMY opened at $53.39 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb Co has a 52-week low of $46.94 and a 52-week high of $70.05. The firm has a market capitalization of $86.49 billion, a PE ratio of 17.74, a P/E/G ratio of 1.48 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. On average, equities analysts anticipate that Bristol-Myers Squibb Co will post 3.88 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Friday, October 5th were given a $0.40 dividend. The ex-dividend date of this dividend was Thursday, October 4th. This represents a $1.60 annualized dividend and a dividend yield of 3.00%. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

A number of research analysts recently weighed in on BMY shares. JPMorgan Chase & Co. upped their price objective on Bristol-Myers Squibb from $70.00 to $74.00 and gave the stock an “overweight” rating in a report on Monday, October 8th. Citigroup downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $62.00 to $57.00 in a research report on Monday, October 22nd. Credit Suisse Group reiterated a “hold” rating and set a $61.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 12th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, October 1st. Finally, William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $62.48.

ILLEGAL ACTIVITY WARNING: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/11/10/smithfield-trust-co-sells-1230-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: Discover Your Risk Tolerance

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply